OCTREOTIDE GH octreotide as acetate 500 micrograms/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide gh octreotide as acetate 500 micrograms/1 ml injection ampoule

generic health pty ltd - octreotide, quantity: 500 microgram - injection, solution - excipient ingredients: glycine; mannitol; dilute hydrochloric acid; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

OCTREOTIDE GH octreotide as acetate 100 micrograms/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide gh octreotide as acetate 100 micrograms/1 ml injection ampoule

generic health pty ltd - octreotide, quantity: 100 microgram - injection, solution - excipient ingredients: glycine; dilute hydrochloric acid; mannitol; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Octreotide 50 micrograms/ml solution for injection Malta - English - Medicines Authority

octreotide 50 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 50 µg/ml - pituitary and hypothalamic hormones and analogues

Octreotide 100 micrograms/ml solution for injection Malta - English - Medicines Authority

octreotide 100 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 100 µg/ml - pituitary and hypothalamic hormones and analogues

Octreotide 500 micrograms/ml solution for injection Malta - English - Medicines Authority

octreotide 500 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 500 µg/ml - pituitary and hypothalamic hormones and analogues

OCTREOTIDE SUN octreotide (as acetate) 50 microgram/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 50 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE SUN octreotide (as acetate) 100 microgram/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 100 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE SUN octreotide (as acetate) 500 microgram/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 500 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE BENDALIS 0.05 MGML Israel - English - Ministry of Health

octreotide bendalis 0.05 mgml

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.05 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

OCTREOTIDE BENDALIS 0.1 MGML Israel - English - Ministry of Health

octreotide bendalis 0.1 mgml

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.1 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.